

In the Claims:

Please cancel claims 1-22 and add the following claims 23-38. Applicant reserves the right to pursue the subject matter of the cancelled claims in future applications. No new matter is added with the addition of new claims 23-38.

For the Examiner's convenience, a "Copy of Pending Claims" is enclosed with this Amendment, in which the claims are listed in an order that the Applicants believe would be appropriate for issue.

Please add the following claims:

--23. (New) An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

24. (New) The polypeptide of claim 23, encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 98% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

25. (New) The polypeptide of claim 23, encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:17 or the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173..

26. (New) An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:18.

27. (New) The polypeptide of claim 26, further comprising an amino acid sequence which is at least 98% identical to the amino acid sequence of SEQ ID NO:18.

28. (New) A naturally occurring allelic variant of a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:18.

29. (New) The naturally occurring allelic variant of claim 28, wherein the polypeptide further comprises an amino acid sequence which is at least 98% identical to the amino acid sequence of SEQ ID NO:18

30. (New) An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof, wherein said polypeptide is soluble, lacks a transmembrane domain and a cytoplasmic domain, and exhibits a human TANGO-69-receptor activity.

31. (New) The polypeptide of claim 30, encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 92.5% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

32. (New) An isolated soluble polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:18, wherein said protein lacks a transmembrane domain and a cytoplasmic domain, and exhibits a human TANGO-69-receptor activity.

33. (New) The polypeptide of claim 32, further comprising an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO:18.

34. (New) The polypeptide of claim 32, further comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:18.

35. (New) The polypeptide of claim 23, further comprising heterologous amino acid sequences.

36. (New) The polypeptide of claim 26, further comprising heterologous amino acid sequences.

37. (New) The polypeptide of claim 30, further comprising heterologous amino acid sequences.

38. (New) The polypeptide of claim 32, further comprising heterologous amino acid sequences.--

Remarks:

Claims 1-22 have been cancelled, and claims 23-38 have been added. No new matter has been added, and support in the specification for the added claims can be found at least beginning at page 12, line 26. The changes made to the specification were merely to correct typographical errors, and support can be found in Tables 1 and 3 (on pages 8 and 9 of the specification).


For the Examiner's convenience, a "**Marked-Up Copy of Amended Portions of the Specification**" (**Appendix A**) is enclosed with this Amendment, wherein text added to the specification is underlined and text deleted from the specification is ~~struck-through~~. Also enclosed is a "**Clean Copy of Amended Portions of the Specification**" (**Appendix B**), in which the amended portions of the specification are shown in their present condition. Also for the Examiner's convenience, a "**Copy of Pending Claims**" (**Appendix C**) is enclosed with this Amendment, in which the claims are listed in an order that the Applicants believe would be appropriate for issue.

Respectfully submitted,

Date: March 3, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By



Paul J. Paglierani
Reg. No. 52,498
75 Sidney Street
Cambridge, MA 02139
(617) 761-6865
(617) 551-8820